Metabolism as a key to histone deacetylase inhibition. Academic Article uri icon


  • There is growing interest in the epigenetic mechanisms that are dysregulated in cancer and other human pathologies. Under this broad umbrella, modulators of histone deacetylase (HDAC) activity have gained interest as both cancer chemopreventive and therapeutic agents. Of the first generation, FDA-approved HDAC inhibitors to have progressed to clinical trials, vorinostat represents a "direct acting" compound with structural features suitable for docking into the HDAC pocket, whereas romidepsin can be considered a prodrug that undergoes reductive metabolism to generate the active intermediate (a zinc-binding thiol). It is now evident that other agents, including those in the human diet, can be converted by metabolism to intermediates that affect HDAC activity. Examples are cited of short-chain fatty acids, seleno--keto acids, small molecule thiols, mercapturic acid metabolites, indoles, and polyphenols. The findings are discussed in the context of putative endogenous HDAC inhibitors generated by intermediary metabolism (e.g. pyruvate), the yin-yang of HDAC inhibition versus HDAC activation, and the screening assays that might be most appropriate for discovery of novel HDAC inhibitors in the future.

published proceedings

  • Crit Rev Biochem Mol Biol

altmetric score

  • 3

author list (cited authors)

  • Rajendran, P., Williams, D. E., Ho, E., & Dashwood, R. H.

citation count

  • 63

complete list of authors

  • Rajendran, Praveen||Williams, David E||Ho, Emily||Dashwood, Roderick H

publication date

  • June 2011